Literature DB >> 20367198

Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease.

Laura Mäkitalo1, Kaija-Leena Kolho, Riitta Karikoski, Hannele Anthoni, Ulpu Saarialho-Kere.   

Abstract

OBJECTIVE: The differential diagnosis of chronic colitis in inflammatory bowel disease (IBD) is challenging and a distinction between Crohn's disease (CD) and ulcerative colitis (UC) is not always possible. Matrix metalloproteinases (MMPs) cleave components of the extracellular matrix and their dysregulation leads to damage to the mucosa. They are involved in inflammation in IBD, as well as in eventual tissue repair. We aimed to examine putative differences in the profiles of MMPs and their tissue inhibitors [tissue inhibitors of metalloproteinase (TIMPs)] in pediatric IBD to find better tools for differential diagnosis of various IBD subgroups at the tissue level in the colon.
MATERIAL AND METHODS: Expression of MMPs -1, -7, -8, -9, -10, -12 and -26 and TIMPs -1 and -3 was studied by immunohistochemistry in colonic tissue samples of 32 pediatric patients with IBD and 11 non-IBD cases.
RESULTS: In the colon, expression of MMP-7 in epithelium was greater in CD samples compared to UC samples (1.09 versus 0.33; P = 0.010). Furthermore, epithelial MMP-10 expression was elevated in CD and UC samples compared to non-IBD samples (1.55 versus 1.00; P = 0.041 and 1.58 versus 1.00; P = 0.025, respectively). TIMP-3 expression in the stroma was higher in both the CD and UC groups when compared to non-IBD samples (2.18 versus 1.36; P = 0.026 and 2.50 versus 1.36; P = 0.002, respectively), but differences between UC and CD could not be observed.
CONCLUSIONS: Increased expression of epithelial MMP-10 and stromal TIMP-3 could serve as histological indicators of IBD etiology. Epithelial MMP-7 expression, on the other hand, could help to differentiate between CD-related colitis and UC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367198     DOI: 10.3109/00365520903583863

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  24 in total

Review 1.  Cellular and molecular mechanisms in the two major forms of inflammatory bowel disease.

Authors:  Laszlo Bene; Andras Falus; Noemi Baffy; Andras Kristof Fulop
Journal:  Pathol Oncol Res       Date:  2011-06-17       Impact factor: 3.201

2.  Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells.

Authors:  Manjula Puthenedam; Feng Wu; Alysha Shetye; Alex Michaels; Ki-Jong Rhee; John H Kwon
Journal:  Inflamm Bowel Dis       Date:  2010-09-01       Impact factor: 5.325

3.  Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses.

Authors:  Jose E Aguirre; Ellen J Beswick; Carl Grim; Gabriela Uribe; Marissa Tafoya; Gabriela Chacon Palma; Von Samedi; Rohini McKee; Romain Villeger; Yuriy Fofanov; Yingzi Cong; Gregory Yochum; Walter Koltun; Don Powell; Irina V Pinchuk
Journal:  Int Immunol       Date:  2020-01-09       Impact factor: 4.823

4.  Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel disease.

Authors:  Kaija-Leena Kolho; Taina Sipponen; Elsa Valtonen; Erkki Savilahti
Journal:  Int J Colorectal Dis       Date:  2014-01       Impact factor: 2.571

5.  Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery.

Authors:  Maija Piekkala; Jaana Hagström; Maarit Tanskanen; Risto Rintala; Caj Haglund; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

6.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

7.  Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Authors:  Chrysanthos Symeonidis; Eleni Papakonstantinou; Asimina Galli; Ioannis Tsinopoulos; Asimina Mataftsi; Spyridon Batzios; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-20       Impact factor: 3.117

8.  Expression and inhibition of matrix metalloproteinase (MMP)-8, MMP-9 and MMP-12 in early colonic anastomotic repair.

Authors:  Peter-Martin Krarup; Mikkel Eld; Katja Heinemeier; Lars Nannestad Jorgensen; Mark Berner Hansen; Magnus S Ågren
Journal:  Int J Colorectal Dis       Date:  2013-04-26       Impact factor: 2.571

Review 9.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

10.  Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis.

Authors:  Laura Mäkitalo; Maija Piekkala; Merja Ashorn; Mikko Pakarinen; Antti Koivusalo; Riitta Karikoski; Johanna Natunen; Ulpu Saarialho-Kere; Risto Rintala; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.